Skip to main content

Press Releases

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.

Kane Biotech Appoints New Advisor

WINNIPEG, Manitoba, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Company,” “Kane Biotech”) today announced that it has entered into an agreement with Harbor Access LLC (“Harbor Access”), an investor relations advisory firm with offices in Canada and the United States.

Harbor Access will provide external Investor Relations services to Kane Biotech in addition to investor outreach throughout North America and Europe. The initial term of the contract will be for four months with a monthly retainer of $8,500 USD.

“We are excited to work with Marc, Ray and the entire Kane Biotech team to build upon their notable accomplishments to date, and look towards refreshing their Investor Relations program. As the company approaches a number of major inflection points, we feel that their story will resonate to a much larger investor audience. Part of our role will be to expand the messaging associated with each of Kane’s commercialization vehicles that are in the process of being created. Our network includes investors based in the US, Canada and Europe and we are very keen to get Kane Biotech management in front of these investors, albeit virtually,” stated Jonathan Paterson, Managing Partner, Harbor Access.

“I am looking forward to working with the Harbor Access team and developing a “Best in Class” Investor Relations program. A key aspect that interested us in Harbor Access is their measured approach to messaging coupled with their investor network. As we expand our investment outreach to beyond Canada; focusing on US and European based investors, Jonathan and his team have the network to support our international efforts,” explained Marc Edwards, CEO, Kane Biotech.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (52 patents and patents pending, trade secrets and trademarks) and products developed by the Company's own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex®, bluestem™, silkstem™, coactiv+™ and Kane® are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE” and on OTCQB Markets under the symbol “KNBIF".

For more information, please visit, or contact:

Marc Edwards
Chief Executive Officer, Kane Biotech Inc.

Ray Dupuis
Chief Financial Officer, Kane Biotech Inc.

Graham Farrell
Investor Relations

+1 (514) 910-6991

+1 (204) 298-2200  

+1 (416) 842-9003

About Harbor Access

Harbor Access represents and advises micro to mega market cap companies. The Company has a measured approach to creating a capital market communications program, which helps optimize their clients’ visibility. Harbor Access brings extensive global experience and professionalism to each client and customizes every solution to meet their clients’ goals.

For more information about Harbor Access, please visit

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information

This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.

COVID-19 Pandemic

The outbreak of COVID-19, the disease caused by the novel SARS-CoV-2 strain of coronavirus, was declared a global pandemic by the World Health Organization on March 11, 2020 and has resulted in a widespread health crisis that has affected economies and financial markets around the world, resulting in an economic downturn. The effects of this pandemic on the Company may include decreased customer demand, interruptions to supply chains, manufacturing activities and research and development programs and increased government regulations or interventions.  The duration and impact of the COVID-19 outbreak is unknown at this time and it is not possible to reliably estimate the length and severity of these developments nor the impact of these developments on the financial results and condition of the Company in future periods.

Kane Logo Cropped TransBG.png

Source: Kane Biotech Inc.